Published in J Bone Miner Res on May 01, 2010
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med (2011) 2.96
Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med (2012) 1.79
Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med (2014) 1.75
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Treating osteoporosis. Aust Prescr (2016) 1.59
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
Individualizing osteoporosis therapy. Osteoporos Int (2012) 1.15
Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol (2011) 1.04
Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol (2015) 0.98
Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab (2011) 0.97
A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis (2011) 0.96
What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. Cost Eff Resour Alloc (2016) 0.95
Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskelet Dis (2013) 0.95
Bisphosphonate drug holiday: choosing appropriate candidates. Curr Osteoporos Rep (2013) 0.93
Current, new and future treatments of osteoporosis. Rheumatol Int (2010) 0.92
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int (2013) 0.88
Do bisphosphonates cause femoral insufficiency fractures? J Orthop Traumatol (2012) 0.87
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis (2016) 0.86
Progress in osteoporosis and fracture prevention: focus on postmenopausal women. Arthritis Res Ther (2009) 0.85
Pathogenesis, management and prevention of atypical femoral fractures. J Bone Metab (2015) 0.83
Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis (2010) 0.82
Comments on Kamimura et al.: significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int (2017) 0.81
Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties. Osteoporos Int (2014) 0.81
Long-term safety concerns of antiresorptive therapy. Rheum Dis Clin North Am (2011) 0.81
The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol (2016) 0.81
If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy. Ther Clin Risk Manag (2011) 0.80
Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations. Ther Adv Chronic Dis (2010) 0.80
Treatment of osteopenia. Rev Endocr Metab Disord (2012) 0.79
Cost-Effectiveness of Osteoporosis Screening Strategies for Men. J Bone Miner Res (2016) 0.79
Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment. PLoS One (2012) 0.78
Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday. HSS J (2015) 0.77
Effect of antiresorptive drugs in the alveolar bone healing. A histometric and immunohistochemical study in ovariectomized rats. Clin Oral Investig (2016) 0.77
Imaging of vertebral fractures. Indian J Endocrinol Metab (2014) 0.77
Atypical femur fracture during bisphosphonate drug holiday: a case series. Osteoporos Int (2015) 0.76
New insights into treatment of osteoporosis in postmenopausal women. RMD Open (2015) 0.76
A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring. J Clin Endocrinol Metab (2014) 0.76
Medical treatment of osteoporotic vertebral fractures. Ther Adv Musculoskelet Dis (2011) 0.76
Osteoporosis Treatment: When to Discontinue and When to Re-start. Bone Res (2013) 0.76
Bone diseases: bisphosphonates in osteoporosis--beyond 5 years. Nat Rev Rheumatol (2013) 0.76
How long should we treat? Osteoporos Int (2014) 0.75
Denosumab after 8 years. Osteoporos Int (2015) 0.75
Update in new medications for primary care. J Gen Intern Med (2010) 0.75
A practical approach to osteoporosis management in the geriatric population. Can Geriatr J (2015) 0.75
Bisphosphonates and atypical subtrochanteric fractures of the femur. Bone Joint Res (2017) 0.75
Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative. J Am Geriatr Soc (2017) 0.75
Management of oral bisphosphonates treatment by rheumatologists and determinants of therapeutic changes: a case-vignette-based study. Osteoporos Int (2017) 0.75
Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int (2016) 0.75
Bisphosphonate therapy: how long is long enough? Osteoporos Int (2015) 0.75
Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. Osteoporos Int (2017) 0.75
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum (2008) 19.80
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med (2014) 11.30
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA (2008) 8.44
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med (2012) 6.85
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet (2009) 6.66
Prognostic value of usual gait speed in well-functioning older people--results from the Health, Aging and Body Composition Study. J Am Geriatr Soc (2005) 6.54
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Effectiveness of acupuncture as adjunctive therapy in osteoarthritis of the knee: a randomized, controlled trial. Ann Intern Med (2004) 5.69
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Effects of estrogen with and without progestin on urinary incontinence. JAMA (2005) 5.41
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38
Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med (2008) 5.34
Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. J Rheumatol (2007) 5.23
Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA (2010) 5.20
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA (2011) 4.83
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res (2003) 4.64
The Aging, Demographics, and Memory Study: study design and methods. Neuroepidemiology (2005) 4.44
Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med (2011) 4.28
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
Clinical use of bone densitometry: scientific review. JAMA (2002) 3.73
Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med (2006) 3.71
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med (2005) 3.56
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med (2010) 3.53
Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med (2007) 3.50
Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med (2005) 3.39
A comparison of prediction models for fractures in older women: is more better? Arch Intern Med (2009) 3.37
Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials. Menopause (2004) 3.33
Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA (2005) 3.30
Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med (2007) 3.27
Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev (2005) 3.20
Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med (2008) 3.20
Duration of lactation and risk factors for maternal cardiovascular disease. Obstet Gynecol (2009) 3.18
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death. Arch Intern Med (2011) 3.17
Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci (2007) 3.16
Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc (2007) 3.15
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res (2002) 3.15
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J Am Soc Nephrol (2005) 3.14
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med (2002) 3.10
Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10